日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

靶向激活的 PI3K/mTOR 信号可克服激素受体阳性乳腺癌临床前模型中对基于 CDK4/6 的疗法的获得性耐药性

Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J Slamon

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

卵巢癌细胞系的综合基因组、表观基因组和表达分析

Eniko Papp, Dorothy Hallberg, Gottfried E Konecny, Daniel C Bruhm, Vilmos Adleff, Michaël Noë, Ioannis Kagiampakis, Doreen Palsgrove, Dylan Conklin, Yasuto Kinose, James R White, Michael F Press, Ronny Drapkin, Hariharan Easwaran, Stephen B Baylin, Dennis Slamon, Victor E Velculescu, Robert B Scharp

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

Abemaciclib 单独使用或与抗有丝分裂和靶向疗法联合使用在乳腺癌中的临床前活性

Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau, Josh Thomas, Ann Mc Nulty, Christophe Marchal, Ondrej Kalous, Erika von Euw, Sara Hurvitz, Colleen Mockbee, Dennis J Slamon